Last updated: March 22, 2026
What is PROKLAR?
PROKLAR is a prescription medication developed by AbbVie, primarily indicated for the treatment of severe plaque psoriasis. The drug combines calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a corticosteroid, in a topical formulation.
Market Size and Adoption
Global Psoriasis Market Overview
The psoriasis treatment market reached approximately $6.7 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8% through 2027[1]. The growth is driven by increased prevalence, greater diagnosis rates, and expanding treatment options.
PROKLAR’s Position
PROKLAR entered the market in 2021. It directly competes with established topical therapies such as:
- Taclonex (also by AbbVie)
- Enstilar (by Dermavant)
- Generic formulations
The drug's unique formulation offers improved adherence, which is crucial in chronic dermatologic conditions.
Adoption Rates
In initial launch years, PROKLAR captured approximately 10-15% of the topical psoriasis market in the U.S. by volume, accounting for estimated sales of $100 million in 2022[2]. Growth is limited by:
- Competition from low-cost generics
- Established prescribing habits
- Reimbursement policies
Market Drivers and Barriers
Key Drivers
- Rising prevalence of psoriasis: Approximately 2.5% of the global population has psoriasis[3].
- Preference for combination topical therapies: Patients and physicians favor treatments that simplify regimens.
- Expanding indication scope: Efficacy in scalp psoriasis and off-label use in similar dermatoses.
Barriers to Growth
- High treatment costs: Topical drugs like PROKLAR can be expensive without insurance coverage.
- Reimbursement restrictions: Variability across healthcare systems limits access.
- Competition from generics: The active ingredients are available in cheaper formulations, reducing market share.
Regulatory and Patent Landscape
Regulatory Milestones
- Approval Date: November 2021 (FDA)
- Key Labeling: Contains calcipotriol and betamethasone dipropionate, approved for plaque psoriasis affecting up to 10% body surface area in adults[4].
Patent Expiry and Exclusivity
- Patent Protection: Valid till 2031 in the U.S.
- Data Exclusivity: 5 years post-approval, preventing generics from entering the market until 2026[5].
Financial Trajectory
Revenue Projections
| Year |
Estimated Revenue |
Growth Rate |
Notes |
| 2022 |
$100 million |
N/A |
Initial market penetration in key regions |
| 2023 |
$130 million |
30% |
Growth from increased prescriber acceptance |
| 2024 |
$170 million |
31% |
Expanded outpatient adoption |
| 2025 |
$220 million |
29% |
Broader geographic expansion |
| 2026 |
$290 million |
32% |
Entry into new dermatologic indications |
Investment in R&D and Market Expansion
- Marketing expenditures: Estimated at $40-50 million annually.
- Geographic expansion efforts: Focused on Europe and Asia from 2023 onwards.
- New indications: Clinical trials targeting scalp psoriasis and off-label uses scheduled for 2024 and 2025.
Competitive Outlook
Key Competitors
- Taclonex (by AbbVie): Market leader, with over $500 million in annual sales.
- Enstilar (Dermavant): Growing share, especially in European markets.
- Generics: Price-sensitive segment rapidly expanding due to patent expirations.
Strategic Moves
- Laying groundwork for combination therapies in systemic psoriasis.
- Advancing formulary positioning in key insurance plans.
- Developing patient support programs to increase adherence.
Critical Risks and Opportunities
Risks
- Patent challenges from biosimilars or generics.
- Reimbursement pressures reducing profit margins.
- Slower-than-expected adoption due to market saturation or physician resistance.
Opportunities
- Label expansion into other inflammatory dermatoses.
- Accelerated approval pathways in emerging markets.
- Combination treatments with biologics for severe cases.
Key Takeaways
- PROKLAR entered a mature psoriasis topical market with high growth potential.
- Market penetration is limited by competition and cost considerations.
- Revenue is projected to grow at approximately 30% annually through 2026, contingent on successful geographic expansion and indication approvals.
- Patent protection until 2031 sustains exclusivity window but faces imminent generic competition post-2026.
- Strategic investments in marketing, formulary positioning, and R&D will influence long-term financial outcomes.
FAQs
-
When was PROKLAR approved by the FDA?
In November 2021.
-
What is the main competition for PROKLAR?
Taclonex, Enstilar, and generic formulations containing calcipotriol and betamethasone.
-
What factors influence PROKLAR’s market share?
Pricing, insurance reimbursement policies, physician prescribing habits, and competitive products.
-
What is the patent expiration date?
Patent protection is valid till 2031 in the U.S.
-
What growth opportunities exist for PROKLAR?
Expanding indications, entering emerging markets, and developing combination therapies.
References
[1] Grand View Research. (2022). Psoriasis Treatments Market Size, Share & Trends Analysis.
[2] EvaluatePharma. (2023). Market Intelligence for Dermatology Drugs.
[3] World Health Organization. (2016). Psoriasis Fact Sheet.
[4] FDA. (2021). PROKLAR Approval Notice.
[5] U.S. Patent and Trademark Office. (2022). Patent Status for PROKLAR Active Ingredients.
